<DOC>
	<DOCNO>NCT01202188</DOCNO>
	<brief_summary>The purpose study provide pivotal efficacy safety data QVA149 patient moderate severe COPD .</brief_summary>
	<brief_title>A Study Assess Efficacy , Safety Tolerability Once-daily ( q.d . ) QVA149 Patients With Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Male female adult age ≥40 yr Smoking history least 10 pack year Diagnosis COPD ( moderatetosevere classify Global Initiative Chronic Obstructive Lung Disease ( GOLD ) Guidelines , 2008 ) Postbronchodilator FEV1 &lt; 80 % ≥ 30 % predict normal value postbronchodilator FEV1/FVC ( force vital capacity ) &lt; 70 % Patients respiratory tract infection within 4 week prior Visit 1 Patients concomitant pulmonary disease Patients history asthma Any patient lung cancer history lung cancer Patients history certain cardiovascular comorbid condition Patients known history diagnosis alpha1 antitrypsin deficiency Patients active phase supervise pulmonary rehabilitation program Patients contraindicate inhaled anticholinergic agent β2 agonists Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>QVA149 , COPD , combination bronchodilator , indacaterol , glycopyrronium bromide</keyword>
</DOC>